AI diagnostic company IDx revealed on Tuesday that it has developed the clinically-aligned autonomous algorithms IDx-DR to identify and detect diabetic retinopathy using artificial intelligence in a growing number of diabetic patient across the US .
The company said IDx-DR, an US FDA-cleared AI system that detects diabetic retinopathy, a leading cause of blindness, now does not require a physician to interpret the images or results. the device allows patients who are at high risk for this blinding eye disease to be tested in non-eye care settings.
More than 30 million Americans have diabetes and an estimated 24,000 lose vision each year from diabetic retinopathy, a complication of diabetes. If caught in its early stages, vision loss and blindness are almost entirely preventable, yet only about half of people with diabetes get regular eye exams.
Recently, a diabetes education centre at a hospital in New Orleans, LA has adopted the company's IDx-DR to enhance their existing diabetic retinopathy detection programme. Their goal is to increase the number of patients they are able to test from 10-13 to over 20 a day.
Additionally, Madhu Mohan, MD, an endocrinologist at Riverside Medical Associates in Riverdale, MD, is now using IDx-DR to test his patients during their regularly scheduled visits, concluded the company.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT